Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 622

1.

Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy.

Labenz C, Toenges G, Huber Y, Nagel M, Marquardt JU, Schattenberg JM, Galle PR, Labenz J, Wörns MA.

Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15515. [Epub ahead of print]

PMID:
31583743
2.

Health-related quality of life in patients with compensated and decompensated liver cirrhosis.

Labenz C, Toenges G, Schattenberg JM, Nagel M, Huber Y, Marquardt JU, Galle PR, Wörns MA.

Eur J Intern Med. 2019 Sep 14. pii: S0953-6205(19)30317-6. doi: 10.1016/j.ejim.2019.09.004. [Epub ahead of print]

PMID:
31530418
3.

Molecular endoscopic imaging: the future is bright.

Ahmed S, Galle PR, Neumann H.

Ther Adv Gastrointest Endosc. 2019 Sep 2;12:2631774519867175. doi: 10.1177/2631774519867175. eCollection 2019 Jan-Dec. Review.

4.

Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.

Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX.

Liver Int. 2019 Aug 22. doi: 10.1111/liv.14223. [Epub ahead of print] Review.

PMID:
31436873
5.

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program.

Huber Y, Pfirrmann D, Gebhardt I, Labenz C, Gehrke N, Straub BK, Ruckes C, Bantel H, Belda E, Clément K, Leeming DJ, Karsdal MA, Galle PR, Simon P, Schattenberg JM.

Aliment Pharmacol Ther. 2019 Oct;50(8):930-939. doi: 10.1111/apt.15427. Epub 2019 Jul 25.

PMID:
31342533
6.

Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre.

Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Wörns MA, Otto G, Zimmermann T, Galle PR.

United European Gastroenterol J. 2019 Jul;7(6):838-849. doi: 10.1177/2050640619840221. Epub 2019 Mar 25.

7.

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G.

Clin Transl Gastroenterol. 2019 Jul;10(7):e00056. doi: 10.14309/ctg.0000000000000056.

8.

Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ.

Vollmar J, Kim YO, Marquardt JU, Becker D, Galle PR, Schuppan D, Zimmermann T.

Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G195-G202. doi: 10.1152/ajpgi.00088.2019. Epub 2019 Jun 26.

PMID:
31241979
9.

The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?

Hahn F, Müller L, Stöhr F, Mähringer-Kunz A, Schotten S, Düber C, Bartsch F, Lang H, Galle PR, Weinmann A, Kloeckner R.

Liver Int. 2019 Jul;39(7):1307-1314. doi: 10.1111/liv.14132. Epub 2019 May 24.

PMID:
31070868
10.

Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.

Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU.

United European Gastroenterol J. 2019 May;7(4):529-537. doi: 10.1177/2050640619825719. Epub 2019 Feb 20.

11.

Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases.

Desuki A, Staib F, Gockel I, Moehler M, Lang H, Biesterfeld S, Maderer A, Galle PR, Berger MR, Schimanski CC.

Can J Gastroenterol Hepatol. 2019 Apr 1;2019:2920493. doi: 10.1155/2019/2920493. eCollection 2019.

12.

High cardiovascular risk in mixed connective tissue disease: evaluation of macrovascular involvement and its predictors by aortic pulse wave velocity.

Triantafyllias K, de Blasi M, Lütgendorf F, Cavagna L, Stortz M, Weinmann-Menke J, Konstantinides S, Galle PR, Schwarting A.

Clin Exp Rheumatol. 2019 Apr 2. [Epub ahead of print]

PMID:
30943141
13.

Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein.

Zhu AX, Finn RS, Galle PR, Llovet JM, Kudo M.

Lancet Oncol. 2019 Apr;20(4):e191. doi: 10.1016/S1470-2045(19)30165-2. No abstract available.

PMID:
30942178
14.

Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation.

Zimmermann A, Darstein F, Hoppe-Lotichius M, Toenges G, Lautem A, Abel F, Schad A, Mittler J, Vollmar J, Grimm D, Lang H, Galle PR, Zimmermann T, Schuppan D.

J Gastrointestin Liver Dis. 2019 Mar;28(1):53-61. doi: 10.15403/jgld.2014.1121.281.crr.

15.

Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD.

Gehrke N, Biedenbach J, Huber Y, Straub BK, Galle PR, Simon P, Schattenberg JM.

Sci Rep. 2019 Mar 8;9(1):4007. doi: 10.1038/s41598-018-38321-9.

16.

Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis.

Labenz C, Toenges G, Huber Y, Nagel M, Marquardt JU, Schattenberg JM, Galle PR, Labenz J, Wörns MA.

Am J Gastroenterol. 2019 May;114(5):764-770. doi: 10.14309/ajg.0000000000000121.

PMID:
30848730
17.

Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization.

Lautem A, Simon F, Hoppe-Lotichius M, Mittler J, Vollmar J, Schad A, Düber C, Galle PR, Otto G, Zimmermann T, Lang H.

Oncol Rep. 2019 Apr;41(4):2299-2310. doi: 10.3892/or.2019.6995. Epub 2019 Feb 1.

PMID:
30720132
18.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
19.

A novel technique for intraduodenal administration of drug suspensions/solutions with concurrent pH monitoring applied to ibuprofen formulations.

Hofmann M, Thieringer F, Nguyen MA, Månsson W, Galle PR, Langguth P.

Eur J Pharm Biopharm. 2019 Mar;136:192-202. doi: 10.1016/j.ejpb.2019.01.010. Epub 2019 Jan 16.

PMID:
30659894
20.

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.

Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T.

BMC Cancer. 2019 Jan 11;19(1):55. doi: 10.1186/s12885-018-5223-7.

21.

Helicobacter pylori Infection as a Risk Factor for Hepatocellular Carcinoma: A Case-Control Study in Ethiopia.

Mekonnen HD, Fisseha H, Getinet T, Tekle F, Galle PR.

Int J Hepatol. 2018 Dec 2;2018:1941728. doi: 10.1155/2018/1941728. eCollection 2018.

22.

Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation.

Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, Galle PR, Romero-Gómez M, Anstee QM, Schattenberg JM; EPoS Consortium Investigators.

Clin Gastroenterol Hepatol. 2019 Sep;17(10):2085-2092.e1. doi: 10.1016/j.cgh.2018.12.016. Epub 2018 Dec 20.

PMID:
30580090
23.

Ginkgo biloba induces different gene expression signatures and oncogenic pathways in malignant and non-malignant cells of the liver.

Czauderna C, Palestino-Dominguez M, Castven D, Becker D, Zanon-Rodriguez L, Hajduk J, Mahn FL, Herr M, Strand D, Strand S, Heilmann-Heimbach S, Gomez-Quiroz LE, Wörns MA, Galle PR, Marquardt JU.

PLoS One. 2018 Dec 21;13(12):e0209067. doi: 10.1371/journal.pone.0209067. eCollection 2018.

24.

Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.

Castven D, Becker D, Czauderna C, Wilhelm D, Andersen JB, Strand S, Hartmann M, Heilmann-Heimbach S, Roth W, Hartmann N, Straub BK, Mahn FL, Franck S, Pereira S, Haupts A, Vogel A, Wörns MA, Weinmann A, Heinrich S, Lang H, Thorgeirsson SS, Galle PR, Marquardt JU.

Int J Cancer. 2019 Jun 1;144(11):2782-2794. doi: 10.1002/ijc.32026. Epub 2018 Dec 14.

PMID:
30485423
25.

[Chronic granulomatous disease as a rare differential diagnosis of inflammatory bowel disease].

Metzger JC, Kurz E, von Spee-Mayer C, Kolck G, Bogumil A, Galle PR, Zimmermann T.

Z Gastroenterol. 2018 Dec;56(12):1507-1512. doi: 10.1055/a-0732-5865. Epub 2018 Nov 22. German.

PMID:
30466133
26.

Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy.

Labenz C, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA.

J Clin Gastroenterol. 2019 Aug;53(7):e303-e307. doi: 10.1097/MCG.0000000000001149.

PMID:
30439761
27.

Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?

Mähringer-Kunz A, Steinle V, Düber C, Weinmann A, Koch S, Schmidtmann I, Schotten S, Hinrichs JB, Graafen D, Pinto Dos Santos D, Galle PR, Kloeckner R.

Liver Int. 2019 Feb;39(2):324-331. doi: 10.1111/liv.13988. Epub 2018 Nov 9.

PMID:
30318826
28.

Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis.

Tang Y, Reissig S, Glasmacher E, Regen T, Wanke F, Nikolaev A, Gerlach K, Popp V, Karram K, Fantini MC, Schattenberg JM, Galle PR, Neurath MF, Weigmann B, Kurschus FC, Hövelmeyer N, Waisman A.

Gastroenterology. 2019 Feb;156(3):692-707.e7. doi: 10.1053/j.gastro.2018.10.023. Epub 2018 Oct 10.

PMID:
30315770
29.

Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.

Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, Galle PR, Wörns MA, Anstee QM, Schuppan D, Schattenberg JM.

Aliment Pharmacol Ther. 2018 Nov;48(10):1109-1116. doi: 10.1111/apt.14976. Epub 2018 Oct 4.

PMID:
30288767
30.

Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real-world cohort.

Darstein F, Häuser F, Straub BK, Wenzel JJ, Conradi R, Mittler J, Lang H, Galle PR, Zimmermann T.

Clin Transplant. 2018 Nov;32(11):e13411. doi: 10.1111/ctr.13411. Epub 2018 Oct 27.

PMID:
30230607
31.

Leaving colorectal polyps in place can be achieved with high accuracy using blue light imaging (BLI).

Neumann H, Neumann Sen H, Vieth M, Bisschops R, Thieringer F, Rahman KF, Gamstätter T, Tontini GE, Galle PR.

United European Gastroenterol J. 2018 Aug;6(7):1099-1105. doi: 10.1177/2050640618769731. Epub 2018 May 17.

32.

Feasibility Trial of the Newly Introduced Optical Enhancement Technology in Patients with Gastroesophageal Reflux Disease.

Thomaidis T, Rahman F, Thieringer F, Tontini GE, Mönkemüller K, Ishaq S, Galle PR, Neumann H.

Dig Dis. 2018;36(6):450-455. doi: 10.1159/000490761. Epub 2018 Aug 28.

33.

Guidelines are silver, but a multidisciplinary team discussion may be golden?

Wörns MA, Galle PR.

Liver Int. 2018 Sep;38(9):1550-1551. doi: 10.1111/liv.13936. No abstract available.

PMID:
30145849
34.

Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy.

Labenz C, Beul L, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA.

Eur J Intern Med. 2019 Feb;60:96-100. doi: 10.1016/j.ejim.2018.08.008. Epub 2018 Aug 19.

PMID:
30131209
35.

Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study.

Vollmar J, Schmid JC, Hoppe-Lotichius M, Barreiros AP, Azizi M, Emrich T, Geber C, Schad A, Weyer V, Otto G, Heise M, Mittler J, Birklein F, Lang H, Galle PR, Zimmermann T.

Transpl Int. 2018 Nov;31(11):1207-1215. doi: 10.1111/tri.13326. Epub 2018 Aug 28.

PMID:
30091268
36.

Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany.

Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D, Spengler U, Strassburg CP, Welker MW, Pischke S, Sterneck M, Mehrabi A, Weiss KH, Herber A, Berg T, Zimmermann T, Galle PR, Heinzow H, Schmidt H, Markova A, Serfert Y, Manns MP, Zeuzem S, Wedemeyer H.

J Hepatol. 2018 Oct;69(4):982-984. doi: 10.1016/j.jhep.2018.07.001. Epub 2018 Aug 6. No abstract available.

PMID:
30089577
37.

Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function.

Schmidt FP, Zimmermann T, Wenz T, Schnorbus B, Ostad MA, Feist C, Grambihler A, Schattenberg JM, Sprinzl MF, Münzel T, Galle PR.

Int J Cardiol. 2018 Nov 15;271:296-300. doi: 10.1016/j.ijcard.2018.04.058. Epub 2018 Aug 1.

PMID:
30077529
38.

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort.

Huber Y, Bierling F, Labenz C, Koch S, Schmidtmann I, Kloeckner R, Schotten S, Huber T, Lang H, Woerns MA, Galle PR, Weinmann A, Weinmann-Menke J.

BMC Cancer. 2018 Jul 31;18(1):774. doi: 10.1186/s12885-018-4677-y.

39.

Ultrasound for Hepatocellular Carcinoma Surveillance: Still Looking for the Fortune Teller.

Foerster F, Galle PR.

Liver Transpl. 2018 Sep;24(9):1167-1168. doi: 10.1002/lt.25309. No abstract available.

40.

Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients.

Labenz C, Baron JS, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA.

Aliment Pharmacol Ther. 2018 Aug;48(3):313-321. doi: 10.1111/apt.14824. Epub 2018 Jun 4.

PMID:
29863286
41.

Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC.

Foerster F, Mittler J, Darstein F, Heise M, Marquardt JU, Wörns MA, Weinmann A, Sälter L, Hoppe-Lotichius M, Heinrich S, Kloeckner R, Pitton MB, Schattenberg JM, Sprinzl MF, Düber C, Otto G, Lang H, Galle PR, Zimmermann T.

Eur J Intern Med. 2018 Sep;55:57-65. doi: 10.1016/j.ejim.2018.05.024. Epub 2018 May 30.

PMID:
29859798
42.

Molecular endoscopic imaging in cancer.

Ahmed S, Strand S, Weinmann-Menke J, Urbansky L, Galle PR, Neumann H.

Dig Endosc. 2018 Nov;30(6):719-729. doi: 10.1111/den.13199. Epub 2018 Jul 5. Review.

PMID:
29846982
43.

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR.

Cancer Treat Rev. 2018 Jul;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. Epub 2018 May 26. Review.

44.

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma.

Mähringer-Kunz A, Weinmann A, Schmidtmann I, Koch S, Schotten S, Pinto Dos Santos D, Pitton MB, Dueber C, Galle PR, Kloeckner R.

BMC Cancer. 2018 Apr 27;18(1):489. doi: 10.1186/s12885-018-4407-5.

45.

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver.

J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5. Review. No abstract available. Erratum in: J Hepatol. 2019 Apr;70(4):817.

PMID:
29628281
46.

The immune contexture of hepatocellular carcinoma predicts clinical outcome.

Foerster F, Hess M, Gerhold-Ay A, Marquardt JU, Becker D, Galle PR, Schuppan D, Binder H, Bockamp E.

Sci Rep. 2018 Mar 29;8(1):5351. doi: 10.1038/s41598-018-21937-2.

47.

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.

Nagel M, Schulz J, Maderer A, Goepfert K, Gehrke N, Thomaidis T, Thuss-Patience PC, Al-Batran SE, Hegewisch-Becker S, Grimminger P, Galle PR, Möhler M, Schattenberg JM.

Tumour Biol. 2018 Mar;40(3):1010428318764007. doi: 10.1177/1010428318764007.

PMID:
29534639
48.

Hepatocellular carcinoma: one world, one cancer-different guidelines?

Foerster F, Galle PR.

Hepatobiliary Surg Nutr. 2018 Feb;7(1):41-43. doi: 10.21037/hbsn.2018.01.05. No abstract available.

49.

The role of molecular enrichment on future therapies in hepatocellular carcinoma.

Nault JC, Galle PR, Marquardt JU.

J Hepatol. 2018 Jul;69(1):237-247. doi: 10.1016/j.jhep.2018.02.016. Epub 2018 Mar 2. Review.

PMID:
29505843
50.

Patient prioritisation in HCC treatment: All (good) things come in threes.

Wörns MA, Galle PR.

J Hepatol. 2018 Jun;68(6):1311-1312. doi: 10.1016/j.jhep.2017.11.035. Epub 2018 Mar 2. No abstract available.

PMID:
29496352

Supplemental Content

Loading ...
Support Center